IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8bio (INAB) filed its Q3 2025 10‑Q, reporting smaller losses as it cut costs and refocused its pipeline. Net loss was $3.9 million for the quarter, an improvement from $7.1 million a year ago, as total operating expenses fell to $4.0 million from $7.1 million. Year-to-date net loss was $14.5 million.
Cash was $10.7 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern, noting current cash is not expected to fund operations for 12 months. During the nine months, IN8bio raised approximately $8.5 million via its ATM program and continued to manage expenses.
The company executed a 1‑for‑30 reverse stock split in June 2025. Shares outstanding were 4,589,196 at September 30, 2025, and 4,634,396 as of November 3, 2025. Pipeline updates include continued encouraging INB‑100 AML data and the previously announced suspension of INB‑400 Phase 2 enrollment to conserve cash.
IN8bio (INAB) reported that it furnished a press release announcing financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The disclosure is provided under Item 2.02 of an 8‑K and, along with Exhibit 99.1, is designated as “furnished,” not “filed,” under the Exchange Act. IN8bio’s common stock trades on Nasdaq under the symbol INAB.
IN8bio, Inc. (INAB) filed an 8-K announcing new preclinical data from its gamma delta T cell engager program, INB-619. The company said the data will be presented at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago.
A company press release with additional details is attached as Exhibit 99.1 and incorporated by reference. This filing does not include financial results or transaction terms; it primarily serves to notify investors of the scientific presentation and provide the related press release.
Alyeska Investment Group and related filers report beneficial ownership of warrants to purchase 89,021 shares of IN8BIO, Inc. common stock, representing 2.58% of the outstanding shares on the stated calculation basis of 3,444,234 shares. The filing shows shared voting and shared dispositive power over the 89,021 warrants, with no sole voting or dispositive power reported. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing is a joint statement by Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh, each acknowledging joint filing responsibilities.
This Amendment No. 2 to a Schedule 13G discloses that Transcend Partners Opportunity Fund I LLC beneficially owns 107,416 shares of IN8bio common stock, representing 2.6% of the class. The percentage is calculated using 4,078,139 shares outstanding as reported as of June 30, 2025. The Reporting Person reports no sole voting or sole dispositive power and instead reports shared voting and shared dispositive power over the shares. Actions regarding these shares require a majority vote of Transcend's managing members, each of whom disclaims beneficial ownership. The amendment is a disclosure of beneficial ownership rather than an indication of control.
IN8bio, Inc. Schedule 13G/A discloses that William Tai-Wei Ho beneficially owns 151,223 shares of common stock, representing 3.7% of the class on a diluted basis. The position comprises 85,112 shares held of record, 4,866 shares held by his minor children, 3,648 shares held by other relatives over which he holds an irrevocable proxy, plus 47,914 options and 9,683 warrants that are immediately or imminently exercisable.
The filing also details voting and dispositive power: 142,709 shares with sole voting and dispositive power and smaller amounts reported as shared power. This amendment updates ownership disclosure but does not show a >5% stake or an intent to control the company.